These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6121576)

  • 1. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.
    Azadkhan AK; Truelove SC; Aronson JK
    Br J Clin Pharmacol; 1982 Apr; 13(4):523-8. PubMed ID: 6121576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.
    Järnerot G; Into-Malmberg MB; Esbjörner E
    Scand J Gastroenterol; 1981; 16(5):693-7. PubMed ID: 6119765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).
    van Hees PA; Tuinte JH; van Rossum JM; van Tongeren JH
    Gut; 1979 Apr; 20(4):300-4. PubMed ID: 36332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats.
    Das KM; Chowdhury JR; Zapp B; Fara JW
    Gastroenterology; 1979 Aug; 77(2):280-4. PubMed ID: 36326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.
    Das KM; Eastwood MA; McManus JP; Sircus W
    Gut; 1973 Aug; 14(8):631-41. PubMed ID: 4147555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
    Allgayer H; Kruis W; Eisenburg J; Paumgartner G
    Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.
    Day JM; Houston JB
    Br J Clin Pharmacol; 1980 Jan; 9(1):91-4. PubMed ID: 6101957
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical pharmacokinetics of sulphasalazine.
    Das KM; Dubin R
    Clin Pharmacokinet; 1976; 1(6):406-25. PubMed ID: 15752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
    Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
    Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease.
    Shaffer JL; Kershaw A; Houston JB
    Br J Clin Pharmacol; 1986 Apr; 21(4):431-5. PubMed ID: 2871853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man.
    Fischer C; Maier K; Stumpf E; von Gaisberg U; Klotz U
    Eur J Clin Pharmacol; 1983; 25(4):511-5. PubMed ID: 6140167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.
    Cowan GO; Das KM; Eastwood MA
    Br Med J; 1977 Oct; 2(6094):1057-9. PubMed ID: 21720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease.
    Astbury C; Taggart AJ; Juby L; Zebouni L; Bird HA
    Ann Rheum Dis; 1990 Aug; 49(8):587-90. PubMed ID: 1975737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the pK values of 5-aminosalicylic acid and N-acetylaminosalicylic acid and comparison of the pH dependent lipid-water partition coefficients of sulphasalazine and its metabolites.
    Allgayer H; Sonnenbichler J; Kruis W; Paumgartner G
    Arzneimittelforschung; 1985; 35(9):1457-9. PubMed ID: 2867770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa.
    Bondesen S; Tage-Jensen U; Jacobsen O; Hansen SH; Rasmussen SN; Hvidberg EF
    Eur J Clin Pharmacol; 1986; 31(1):23-6. PubMed ID: 2877884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulphasalazine: a review of 40 years' experience.
    Watkinson G
    Drugs; 1986; 32 Suppl 1():1-11. PubMed ID: 2877847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats.
    Shafii A; Chowdhury JR; Das KM
    Am J Gastroenterol; 1982 May; 77(5):297-9. PubMed ID: 6123257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.